Association of PPI and antibiotics with the clinical outcomes of HCC patients receiving atezolizumab and bevacizumab: A multicenter analysis.
Takeshi HatanakaSatoru KakizakiAtsushi HiraokaToshifumi TadaMasashi HirookaKazuya KariyamaJoji TaniMasanori AtsukawaKoichi TakaguchiEi ItobayashiShinya FukunishiKunihiko TsujiToru IshikawaKazuto TajiriHironori OchiSatoshi YasudaHidenori ToyodaChikara OgawaTakashi NishimuraNoritomo ShimadaKazuhito KawataHisashi KosakaAtsushi NaganumaYutaka YataTakaaki TanakaHideko OhamaFujimasa TadaKazuhiro NousoAsahiro MorishitaAkemi TsutsuiTakuya NaganoNorio ItokawaTomomi OkuboTaeang AraiMichitaka ImaiYohei KoizumiShinichiro NakamuraMasaki KaiboriHiroko IijimaYoichi HiasaTakashi KumadaPublished in: Hepatology research : the official journal of the Japan Society of Hepatology (2023)
The therapeutic outcomes of Atez/Bev in HCC patients did not differ between patients with and without PPI treatment or between patients with and without antibiotic treatment. This article is protected by copyright. All rights reserved.